Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of option grant

The calculated value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

	2016		2015		2014
Risk-free interest rate		1.40% – 2.03%		1.93% – 2.21%		0.3–2.2%
Expected dividend yield		0%		0%		0%
Expected volatility		47.6% – 48.2%		47.5% – 50.4%		50.0%–61.2%
Expected term		6.25 years		6.25 – 6.5 years		1.5–6.5 years
Weighted-average grant date calculated fair value	$	1.97	$	6.17	$	4.73

Schedule of stock option activity

A summary of stock option activity for the years ended December 31, 2016, 2015 and 2014 is presented below (in thousands, except per share and contractual life data):

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)
Options outstanding at December 31, 2013		2,241		$	4.84
Granted		1,378			7.62
Exercised		(115	)		4.40
Forfeited or expired		(252	)		4.44
Options outstanding at December 31, 2014		3,252		$	6.07
Granted		998			12.29
Exercised		(574	)		4.85
Forfeited or expired		(204	)		7.08
Options outstanding at December 31, 2015		3,472		$	8.01
Granted		745			4.18
Exercised		(96	)		5.00
Forfeited or expired		(454	)		8.66
Options outstanding at December 31, 2016		3,667		$	7.23		6.27
Options exercisable at December 31, 2016		1,954		$	6.66		4.29

Schedule of exercise prices of common stock options outstanding and exercisable

The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2016 (in thousands):

Exercise Price		Options Outstanding (Shares)		Options Exercisable (Shares)
$	2.34  to   4.25		627		125
$	4.88  to   5.23		1,430		1,168
$	7.00  to   9.01		842		415
$	12.43  to 14.06		768		246
			3,667		1,954

Schedule of restricted stock unit (RSU) activity

The following table presented below summarizes Restricted Stock Unit (RSU) activity for the years ended December 31, 2016 and 2015 (in thousands, except per share data):

	Number of Awards		Weighted Average Grant Date Fair Value Per Share
Outstanding as of December 31, 2014		-	$	-
Awarded		190		12.43
Vested		-		-
Forfeited/canceled		-		-
Outstanding as of December 31, 2015		190	$	12.43
Awarded		-		-
Vested		59		12.43
Forfeited/canceled		-		-
Outstanding as of December 31, 2016		131	$	12.43

Schedule of stock-based compensation

The total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the years ended December 31, 2016, 2015 and 2014 is as follows (in thousands):

	2016		2015		2014
Cost of sales	$	312	$	279	$	192
Research and development		303		208		293
Clinical and regulatory		173		235		113
Selling and marketing		104		442		141
General and administrative		2,475		1,523		736
Total	$	3,367	$	2,687	$	1,475